|Last Update: 05/23/13 - 4:01 PM EDT|
|YTD Performance: 13.01%|
|Previous Close: $65.25|
|52 Week Range: $50.25 - $68.83|
|Oustanding Shares: 470,474,681|
|Market Cap: 30,957,234,010|
|Qtr (06/13)||Qtr (09/13)||FY (09/13)||FY (09/14)|
|Number of Analysts||7||7||12||10|
|Growth Rate (Year over Year)||-16.02%||-10.22%||-9.17%||9.86%|
Safety stocks aren’t every going to be crushed, but could certainly stumble.
The move seems sure to unlock value, but you might want to hold off a bit for a solid entry point.
Shares of COV now seen reaching $66, Jefferies said. Estimates also raised as COV stays ahead of the pack. Buy rating.
Dan Fitzpatrick examines three stocks viewed onFast Money. Today's stocks include Amgen, Gilead, and Celgene.
Shares of COV now seen reaching $61, Jefferies said. New product story supports continued growth. Buy rating.
COV was downgraded to Neutral, Goldman Sachs said. Company is facing lower end-market demand.
COV target was boosted to $53, Goldman Sachs said. Pharma spin-off should help unlock value. Buy rating.
Here's a look at today's top research calls.